Home/Filings/4/0001567619-21-002634
4//SEC Filing

LAV Biosciences Fund V, L.P. 4

Accession 0001567619-21-002634

CIK 0001831363other

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 5:00 PM ET

Size

28.4 KB

Accession

0001567619-21-002634

Insider Transaction Report

Form 4
Period: 2021-02-09
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,392,8571,392,857 total(indirect: See footnotes)
  • Conversion

    Series A Preferred Stock

    2021-02-091,392,8570 total(indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Conversion

    Series C Preferred Stock

    2021-02-091,405,5830 total(indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Conversion

    Common Stock

    2021-02-09+696,428696,428 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+1,286,6981,286,698 total(indirect: See footnotes)
  • Conversion

    Series B Preferred Stock

    2021-02-09952,3800 total(indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,405,5831,405,583 total(indirect: See footnotes)
  • Conversion

    Series A Preferred Stock

    2021-02-09696,4280 total(indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Conversion

    Series C Preferred Stock

    2021-02-09334,3180 total(indirect: See footnotes)
    Common Stock (334,318 underlying)
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,392,8571,392,857 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+696,428696,428 total(indirect: See footnotes)
  • Conversion

    Series C Preferred Stock

    2021-02-091,405,5830 total(indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Conversion

    Series A Preferred Stock

    2021-02-091,392,8570 total(indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,286,6981,286,698 total(indirect: See footnotes)
  • Conversion

    Series A Preferred Stock

    2021-02-09696,4280 total(indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Conversion

    Series B Preferred Stock

    2021-02-09952,3800 total(indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,405,5831,405,583 total(indirect: See footnotes)
  • Conversion

    Series C Preferred Stock

    2021-02-09334,3180 total(indirect: See footnotes)
    Common Stock (334,318 underlying)
Transactions
  • Conversion

    Series C Preferred Stock

    2021-02-09334,3180 total(indirect: See footnotes)
    Common Stock (334,318 underlying)
  • Conversion

    Common Stock

    2021-02-09+696,428696,428 total(indirect: See footnotes)
  • Conversion

    Series A Preferred Stock

    2021-02-091,392,8570 total(indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Conversion

    Series A Preferred Stock

    2021-02-09696,4280 total(indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Conversion

    Series C Preferred Stock

    2021-02-091,405,5830 total(indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,392,8571,392,857 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+1,286,6981,286,698 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+1,405,5831,405,583 total(indirect: See footnotes)
  • Conversion

    Series B Preferred Stock

    2021-02-09952,3800 total(indirect: See footnotes)
    Common Stock (952,380 underlying)
LAV Aqua Ltd
10% Owner
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,392,8571,392,857 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+696,428696,428 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2021-02-09+1,405,5831,405,583 total(indirect: See footnotes)
  • Conversion

    Series B Preferred Stock

    2021-02-09952,3800 total(indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Conversion

    Series C Preferred Stock

    2021-02-09334,3180 total(indirect: See footnotes)
    Common Stock (334,318 underlying)
  • Conversion

    Series C Preferred Stock

    2021-02-091,405,5830 total(indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Conversion

    Series A Preferred Stock

    2021-02-09696,4280 total(indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,286,6981,286,698 total(indirect: See footnotes)
  • Conversion

    Series A Preferred Stock

    2021-02-091,392,8570 total(indirect: See footnotes)
    Common Stock (1,392,857 underlying)
Footnotes (8)
  • [F1]Each share of Series A Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F2]Shares held by Hopewell Resources Holdings Limited.
  • [F3]Shares held by Oriental Spring Venture Limited.
  • [F4]Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F5]Shares held by LAV Aqua Limited.
  • [F6]Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F7]Shares held by LAV Biosciences Fund V, L.P.
  • [F8]LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.

Documents

1 file

Issuer

Terns Pharmaceuticals, Inc.

CIK 0001831363

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001764435

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 5:00 PM ET
Size
28.4 KB